Italian researchers from the University of of Salento in Lecce recently published findings from their study of a potentially groundbreaking mesothelioma cancer treatment that could drastically improve the prognosis of patients with what is considered to be one of the more difficult types of cancer to treat. The study researched how well lab rats with particular mesothelioma tumors responded to two experimental drugs, Ptac2S and cisplatin, and whether either of the two treatments could potentially translate into benefits for human patients.
Sarcomatous mesothelioma, also known as diffuse malignant fibrous and spindled mesothelioma, is one of the less common forms of the disease, affecting an estimated 7 to 20% of mesothelioma cancer patients. Diagnosis is often more difficult with this particular form of the disease as the tumor cells tend to mimic other types of benign and deadly cancers under traditional diagnostic methods like x-rays, CT scans, and MRI.
The results of the study were promising, with injections of Ptac2S reducing tumor growth by 50% and shrinking tumor mass by 53%. On the other hand, lab rats treated with cisplatin reduced tumor size by 12%, a significantly smaller impact than Ptac2S but still positive treatment option. The results of Ptac2S treatments from the Italian study reinforce previous research showing the drug to be 12 times more effective at fighting certain cancer cells than cisplatin.